Najat C Daw1, Yueh-Yun Chi2, John A Kalapurakal3, Yeonil Kim2, Fredric A Hoffer4, James I Geller5, Elizabeth J Perlman6, Peter F Ehrlich7, Elizabeth A Mullen8, Anne B Warwick9, Paul E Grundy10, Arnold C Paulino11, Eric Gratias12, Deborah Ward13, James R Anderson14, Geetika Khanna15, Brett Tornwall2, Conrad V Fernandez16, Jeffrey S Dome17. 1. Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX. 2. Department of Biostatistics, University of Florida, Gainesville, FL. 3. Department of Radiation Oncology, Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern Memorial Hospital, Chicago, IL. 4. Department of Radiology, University of Washington, Seattle, WA. 5. Division of Oncology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH. 6. Department of Pathology, Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL. 7. Department of Pediatric Surgery, C.S. Mott Children's Hospital, University of Michigan, Ann Arbor, MI. 8. Department of Pediatric Hematology/Oncology, Dana-Farber/Harvard Cancer Center, Dana-Farber Cancer Institute, Boston, MA. 9. Department of Pediatrics, F. Edward Hébert School of Medicine, Uniformed Services University, Bethesda, MD. 10. Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada. 11. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. 12. University of Tennessee College of Medicine-Chattanooga, Chattanooga, TN. 13. Department of Pharmaceutical Services, St Jude Children's Research Hospital, Memphis, TN. 14. University of Nebraska Medical Center, Omaha, NE. 15. Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, MO. 16. Departments of Pediatrics and Bioethics, IWK Health Centre, Dalhousie University, Halifax, Nova Scotia, Canada. 17. Division of Oncology, Children's National Medical Center, Center for Cancer and Blood Disorders, George Washington University School of Medicine and Health Sciences, Washington, DC.
Abstract
PURPOSE: AREN0321 evaluated the activity of vincristine and irinotecan (VI) in patients with newly diagnosed diffuse anaplastic Wilms tumor (DAWT) and whether a regimen containing carboplatin (regimen UH1) in addition to regimen I agents used in the National Wilms Tumor Study 5 (NWTS-5; vincristine, doxorubicin, cyclophosphamide, and etoposide plus radiotherapy) would improve patient outcomes. PATIENTS AND METHODS: Patients with stage II to IV DAWT without measurable disease received regimen UH1. Patients with stage IV measurable disease were eligible to receive VI (vincristine, 1.5 mg/m2 per day intravenously on days 1 and 8; irinotecan, 20 mg/m2 per day intravenously on days 1-5 and 8-12 of a 21-day cycle) in an upfront window; those with complete (CR) or partial response (PR) had VI incorporated into regimen UH1 (regimen UH2). The study was designed to detect improvement in outcomes of patients with stage II to IV DAWT compared with historical controls treated with regimen I. RESULTS: Sixty-six eligible patients were enrolled. Of 14 patients with stage IV measurable disease who received VI, 11 (79%) achieved CR (n = 1) or PR (n = 10) after 2 cycles. Doses of doxorubicin, cyclophosphamide, and etoposide were reduced midstudy because of nonhematologic toxicity. Four patients (6%) died as a result of toxicity. Four-year event-free survival, relapse-free survival, and overall survival rates were 67.7% (95% CI, 55.9% to 79.4%), 72.9% (95% CI, 61.5% to 84.4%), and 73.7% (95% CI, 62.7% to 84.8%), respectively, compared with 57.5% (95% CI, 47.6% to 67.4%; P = .26), 57.5% (95% CI, 47.6% to 67.4%; P = .048), and 59.2% (95% CI, 49.4% to 69.0%; P = .08), respectively, in NWTS-5. CONCLUSION: VI produced a high response rate in patients with metastatic DAWT. AREN0321 treatment seemed to improve outcomes for patients with stage II to IV DAWT compared with NWTS-5, but with increased toxicity. The UH2 regimen warrants further investigation with modifications to reduce toxicity.
PURPOSE:AREN0321 evaluated the activity of vincristine and irinotecan (VI) in patients with newly diagnosed diffuse anaplastic Wilms tumor (DAWT) and whether a regimen containing carboplatin (regimen UH1) in addition to regimen I agents used in the National Wilms Tumor Study 5 (NWTS-5; vincristine, doxorubicin, cyclophosphamide, and etoposide plus radiotherapy) would improve patient outcomes. PATIENTS AND METHODS: Patients with stage II to IV DAWT without measurable disease received regimen UH1. Patients with stage IV measurable disease were eligible to receive VI (vincristine, 1.5 mg/m2 per day intravenously on days 1 and 8; irinotecan, 20 mg/m2 per day intravenously on days 1-5 and 8-12 of a 21-day cycle) in an upfront window; those with complete (CR) or partial response (PR) had VI incorporated into regimen UH1 (regimen UH2). The study was designed to detect improvement in outcomes of patients with stage II to IV DAWT compared with historical controls treated with regimen I. RESULTS: Sixty-six eligible patients were enrolled. Of 14 patients with stage IV measurable disease who received VI, 11 (79%) achieved CR (n = 1) or PR (n = 10) after 2 cycles. Doses of doxorubicin, cyclophosphamide, and etoposide were reduced midstudy because of nonhematologic toxicity. Four patients (6%) died as a result of toxicity. Four-year event-free survival, relapse-free survival, and overall survival rates were 67.7% (95% CI, 55.9% to 79.4%), 72.9% (95% CI, 61.5% to 84.4%), and 73.7% (95% CI, 62.7% to 84.8%), respectively, compared with 57.5% (95% CI, 47.6% to 67.4%; P = .26), 57.5% (95% CI, 47.6% to 67.4%; P = .048), and 59.2% (95% CI, 49.4% to 69.0%; P = .08), respectively, in NWTS-5. CONCLUSION: VI produced a high response rate in patients with metastatic DAWT. AREN0321 treatment seemed to improve outcomes for patients with stage II to IV DAWT compared with NWTS-5, but with increased toxicity. The UH2 regimen warrants further investigation with modifications to reduce toxicity.
Authors: F Pein; M F Tournade; J M Zucker; M Brunat-Mentigny; A Deville; P Boutard; F Dusol; J C Gentet; E Legall; F Mechinaud Journal: J Clin Oncol Date: 1994-05 Impact factor: 44.544
Authors: D M Green; J B Beckwith; N E Breslow; P Faria; J Moksness; J Z Finklestein; P Grundy; P R Thomas; T Kim; S Shochat Journal: J Clin Oncol Date: 1994-10 Impact factor: 44.544
Authors: A M Abu-Ghosh; M D Krailo; S C Goldman; R S Slack; V Davenport; E Morris; J H Laver; G H Reaman; M S Cairo Journal: Ann Oncol Date: 2002-03 Impact factor: 32.976
Authors: Peter Ehrlich; Yuen Y Chi; Murali M Chintagumpala; Fred A Hoffer; Elizabeth J Perlman; John A Kalapurakal; Ann Warwick; Robert C Shamberger; Geetika Khanna; Tom E Hamilton; Ken W Gow; Arnold C Paulino; Eric J Gratias; Elizabeth A Mullen; James I Geller; Paul E Grundy; Conrad V Fernandez; Michael L Ritchey; James S Dome Journal: Ann Surg Date: 2017-09 Impact factor: 12.969
Authors: A Weirich; R Ludwig; N Graf; U Abel; I Leuschner; G M Vujanic; O Mehls; J Boos; J Beck; B Royer-Pokora; P A Voûte Journal: Ann Oncol Date: 2004-05 Impact factor: 32.976
Authors: Jeffrey S Dome; Elizabeth A Mullen; David B Dix; Eric J Gratias; Peter F Ehrlich; Najat C Daw; James I Geller; Murali Chintagumpala; Geetika Khanna; John A Kalapurakal; Lindsay A Renfro; Elizabeth J Perlman; Paul E Grundy; Conrad V Fernandez Journal: J Natl Compr Canc Netw Date: 2021-08-01 Impact factor: 11.908
Authors: Murali M Chintagumpala; Elizabeth J Perlman; Brett Tornwall; Yueh-Yun Chi; Yeonil Kim; Fredric A Hoffer; John A Kalapurakal; Anne B Warwick; Robert C Shamberger; Geetika Khanna; Thomas E Hamilton; Kenneth W Gow; Arnold C Paulino; Eric J Gratias; Elizabeth A Mullen; James I Geller; Conrad V Fernandez; Michael L Ritchey; Paul E Grundy; Jeffrey S Dome; Peter F Ehrlich Journal: Cancer Date: 2022-04-05 Impact factor: 6.921
Authors: Andrew D Woods; Noah E Berlow; Michael V Ortiz; Filemon Dela Cruz; Armaan Siddiquee; Diego F Coutinho; Reshma Purohit; Katherine E Tranbarger Freier; Joel E Michalek; Melvin Lathara; Kevin Matlock; Ganapati Srivivasa; Brigitte Royer-Pokora; Renata Veselska; Andrew L Kung; Charles Keller Journal: Pediatr Blood Cancer Date: 2021-10-24 Impact factor: 3.838
Authors: M E Madeleine van der Perk; Nicholas G Cost; Annelies M E Bos; Robert Brannigan; Tanzina Chowdhury; Andrew M Davidoff; Najat C Daw; Jeffrey S Dome; Peter Ehrlich; Norbert Graf; James Geller; John Kalapurakal; Kathleen Kieran; Marcus Malek; Mary F McAleer; Elizabeth Mullen; Luke Pater; Angela Polanco; Rodrigo Romao; Amanda F Saltzman; Amy L Walz; Andrew D Woods; Marry M van den Heuvel-Eibrink; Conrad V Fernandez Journal: Int J Cancer Date: 2022-05-11 Impact factor: 7.316